Literature DB >> 17158897

Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant.

Jeannette N Williams1, Paul J Skipp, Holly E Humphries, Myron Christodoulides, C David O'Connor, John E Heckels.   

Abstract

Current experimental vaccines against serogroup B Neisseria meningitidis are based on meningococcal outer membrane (OM) proteins present in outer membrane vesicles (OMV) in which toxic lipopolysaccharide is depleted by detergent extraction. Knowledge of the composition of OM and OMV is essential for developing new meningococcal vaccines based on defined antigens. In the current study, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and nanocapillary liquid chromatography-tandem mass spectrometry were used to investigate the proteomes of OM and OMV from meningococcal strain MC58 and OM from a lipopolysaccharide-deficient mutant. The analysis of OM revealed a composition that was much more complex than the composition that has been reported previously; a total of 236 proteins were identified, only 6.4% of which were predicted to be located in the outer membrane. The most abundant proteins included not only the well-established major OM proteins (PorA, PorB, Opc, Rmp, and Opa) but also other proteins, such as pilus-associated protein Q (PilQ) and a putative macrophage infectivity protein. All of these proteins were also present in OMV obtained by extraction of the OM with deoxycholate. There were markedly increased levels of some additional proteins in OM from the lipopolysaccharide-deficient mutant, including enzymes that contribute to the tricarboxylic acid cycle. In all the preparations, the proteins not predicted to have an OM location were predominantly periplasmic or cytoplasmic or had an unknown location, and relatively few cytoplasmic membrane proteins were detected. However, several proteins that have previously been identified as potential vaccine candidates were not detected in either OM preparations or in OMV. These results have important implications for the development and use of vaccines based on outer membrane proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158897      PMCID: PMC1828559          DOI: 10.1128/IAI.01424-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  55 in total

Review 1.  Impact of meningococcal C conjugate vaccine in the UK.

Authors:  P Balmer; R Borrow; E Miller
Journal:  J Med Microbiol       Date:  2002-09       Impact factor: 2.472

2.  Characterization of naturally elaborated blebs from serum-susceptible and serum-resistant strains of Neisseria gonorrhoeae.

Authors:  R K Pettit; R C Judd
Journal:  Mol Microbiol       Date:  1992-03       Impact factor: 3.501

3.  Robust method for proteome analysis by MS/MS using an entire translated genome: demonstration on the ciliome of Tetrahymena thermophila.

Authors:  Jeffrey C Smith; Julian G B Northey; Jyoti Garg; Ronald E Pearlman; K W Michael Siu
Journal:  J Proteome Res       Date:  2005 May-Jun       Impact factor: 4.466

4.  Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254.

Authors:  Caroline Vipond; Janet Suker; Christopher Jones; Christoph Tang; Ian M Feavers; Jun X Wheeler
Journal:  Proteomics       Date:  2006-06       Impact factor: 3.984

5.  Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection.

Authors:  D Martin; N Cadieux; J Hamel; B R Brodeur
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

6.  Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells.

Authors:  M Virji; K Makepeace; D J Ferguson; M Achtman; E R Moxon
Journal:  Mol Microbiol       Date:  1993-11       Impact factor: 3.501

7.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

8.  Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci.

Authors:  Myron Christodoulides; Joy L Brooks; Elizabeth Rattue; John E Heckels
Journal:  Microbiology (Reading)       Date:  1998-11       Impact factor: 2.777

9.  Proteome analysis of Neisseria meningitidis serogroup A.

Authors:  Giulia Bernardini; Giovanni Renzone; Maurizio Comanducci; Roberta Mini; Simona Arena; Chiara D'Ambrosio; Stefania Bambini; Lorenza Trabalzini; Guido Grandi; Paola Martelli; Mark Achtman; Andrea Scaloni; Giulio Ratti; Annalisa Santucci
Journal:  Proteomics       Date:  2004-10       Impact factor: 3.984

10.  Structural comparison of Neisseria gonorrhoeae outer membrane proteins.

Authors:  J E Heckels
Journal:  J Bacteriol       Date:  1981-02       Impact factor: 3.490

View more
  30 in total

1.  Proteomic characterization of the whole secretome of Legionella pneumophila and functional analysis of outer membrane vesicles.

Authors:  Frank Galka; Sun Nyunt Wai; Harald Kusch; Susanne Engelmann; Michael Hecker; Bernd Schmeck; Stefan Hippenstiel; Bernt Eric Uhlin; Michael Steinert
Journal:  Infect Immun       Date:  2008-02-04       Impact factor: 3.441

2.  A Neisseria meningitidis NMB1966 mutant is impaired for invasion of respiratory epithelial cells, survival in human blood and for virulence in vivo.

Authors:  Ming-Shi Li; Noel Y S Chow; Sunita Sinha; Denise Halliwell; Michelle Finney; Andrew R Gorringe; Mark W Watson; J Simon Kroll; Paul R Langford; Steven A R Webb
Journal:  Med Microbiol Immunol       Date:  2008-12-03       Impact factor: 3.402

3.  Comparative proteome analysis of spontaneous outer membrane vesicles and purified outer membranes of Neisseria meningitidis.

Authors:  Martin Lappann; Andreas Otto; Dörte Becher; Ulrich Vogel
Journal:  J Bacteriol       Date:  2013-07-26       Impact factor: 3.490

4.  Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates.

Authors:  Jeannette N Williams; Paul J Skipp; C David O'Connor; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

5.  The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.

Authors:  Miao-Chiu Hung; Omar Salim; Jeannette N Williams; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

Review 6.  A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.

Authors:  Yordanka Masforrol; Jeovanis Gil; Darien García; Jesús Noda; Yassel Ramos; Lázaro Betancourt; Osmany Guirola; Sonia González; Boris Acevedo; Vladimir Besada; Osvaldo Reyes; Luis Javier González
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

Review 7.  Review of meningococcal group B vaccines.

Authors:  Dan M Granoff
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

8.  Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.

Authors:  Magdalena K Bielecka; Nathalie Devos; Mélanie Gilbert; Miao-Chiu Hung; Vincent Weynants; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

9.  The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection.

Authors:  John E Heckels; Jeannette N Williams
Journal:  Genome Med       Date:  2010-07-22       Impact factor: 11.117

10.  A cyanobacterial lipopolysaccharide antagonist inhibits cytokine production induced by Neisseria meningitidis in a human whole-blood model of septicemia.

Authors:  Kim Jemmett; Annalisa Macagno; Monica Molteni; John E Heckels; Carlo Rossetti; Myron Christodoulides
Journal:  Infect Immun       Date:  2008-04-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.